June 15, 2007 - Avid Radiopharmaceuticals Inc. announced that a preclinical study presented at at the Society of Nuclear Medicine (SNM) Annual Meeting was selected as the 2007 Small Animal Image of the Year, showing a Positron Emission Tomography (PET) image of a rat pancreas following injection with AV-133, a molecular imaging agent.

The image highlighted the presentation entitled: “F-18 FP-DTBZ: An Investigational PET Ligand for Measuring Beta Cell Mass in the Pancreas,” with Drs. Mei-Ping Kung and Hank Kung as primary investigators. This study showed that AV-133, targeting the vesicular monoamine transporter-2 (VMAT2), is potentially useful for measurement of beta cell mass and for studying the pathogenesis of diabetes.

Declines in the number of beta cells in the pancreas are evident prior to the onset of diabetes and may be a useful early marker for increased risk of developing Type I or Type II diabetes. The amount of vesicular monoamine transporter (VMAT2), which is expressed by the beta cells of the pancreas, may reflect beta cell mass. Molecular imaging of beta cells using a VMAT2-targeted compound has the potential to detect losses in beta cells before a diagnosis of diabetes is possible by current methods. This may make it possible to identify individuals who are at elevated risk of developing diabetes to receive earlier treatment, and allow for monitoring of new treatments designed to preserve beta cells.

There are 20.8 million children and adults with diabetes in the United States alone (7 percent of the population). Diabetes mellitus (DM) is on the rise globally and is associated with an increased risk for serious, life-threatening complications including heart disease and stroke. Proactive disease control can help reduce risk; however, many people are not aware that they are at risk of diabetes until they develop one of its complications.

For more information: www.avidrp.com


Related Content

News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
arrow
News | Prostate Cancer

January 5, 2024 — Perspective Therapeutics, Inc., announced that it has entered into a patent license agreement with ...

Time January 05, 2024
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
News | Quality Assurance (QA)

November 25, 2023 — Mirion announced that it will debut the new Instadose VUE personal dosimeter, from its Dosimetry ...

Time November 25, 2023
arrow
News | PET-CT

November 22, 2023 — Siemens Healthineers has announced the U.S. Food and Drug Administration (FDA) clearance of the ...

Time November 22, 2023
arrow
News | Artificial Intelligence

November 21, 2023 — Heuron, a medical AI (artificial intelligence) imaging software solution company, under the ...

Time November 21, 2023
arrow
News | Information Technology

November 21, 2023 — GE HealthCare has received U.S. FDA 510(k) Clearance for the new version of Digital Expert Access ...

Time November 21, 2023
arrow
News | Radiopharmaceuticals and Tracers

October 20, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease ...

Time October 20, 2023
arrow
Subscribe Now